



## **Sun Pharma announces the FDA approval for Ximino**

20 August 2015 | News | By BioSpectrum Bureau

### **Sun Pharma announces the FDA approval for Ximino**

Sun Pharmaceutical has announced that the US Food and Drug Administration (US FDA) has approved its Supplemental New Drug Application (sNDA) for Ximino (Minocycline HCl) extended-release capsules 45 mg, 90 mg and 135 mg.

Ximino extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

This approval further strengthens the Company's branded dermatology portfolio in the US. It expects Ximino extended-release capsules to be available for patients during the fourth quarter of 2015.